SK
SHIV RAM KRISHN
Thomas Jefferson University, University of Nebraska Medical Center
0000-0002-4770-6671
Employment
-
Thomas Jefferson University Post-doctoral Research Fellow2017 - Present
-
University of Nebraska Medical Center Research Assistant2016 - 2016
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (28)
- Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth Save
- Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth Save
- Supplementary Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth Save
- Supplementary Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth Save
- BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth Save
- Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth Save
- Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth Save
- Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth Save
- Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth Save
- Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth Save